AbbVie Inc. (ABBV) : Admission to the Million Leaf Investment UnAbbVie Inc. is a global, research-driven biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative therapies. The company targets diseases with significant unmet medical needs, emphasizing long-term treatment franchises supported by scientifi
AbbVie, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.14 EUR
4.09 B EUR
54.42 B EUR
1.77 B
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
IPO date
Jan 2, 2013
Identifiers
3
ISIN US00287Y1091
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
ABBV Stock Analysis [1D TF]
Fundamental/Market Context
AbbVie (ABBV) continues to benefit from a diversified portfolio led by strong immunology and oncology franchises. Recent earnings have generally topped expectations, supporting confidence in cash flow and dividend sustainability, while pipeline catalysts provide medium-t
ABBVIE topped and looks for a 2026 Bear Cycle.AbbVie Inc. (ABBV) has been trading within a Channel Up for almost the past 4 years (since the April 04 2022 High) and seems to have topped on its latest September 29 2025 Higher High as it turned sideways since.
On that September top, the 1W RSI also got rejected from overbought territory, which i
Healthy Pullback or Trend Reversal?Bullish Scenario (Primary)
• Strong uptrend structure
• Sharp impulse move followed by bullish consolidation (triangle)
• Pullback is constructive, not trend-breaking
• Price holding above 50-day SMA
📍 Entry Zone:
• $225 – $230
🛑 Stop Loss:
• $212
• Daily close below invalidates bullish se
ABBV Undervalued Pharma? Strong Dividend Play?ABBV – Financial Performance & SWOT Analysis
ABBV Undervalued Pharma? Strong Dividend Play?
(1/9)
Good evening, folks! ABBV is climbing 🚀, at $ 230.69 up 33.40% YTD per October 10, 2025. Q2 revenue shakes up this pharma play , let’s dive in! 📊🔥 Tag a friend who needs this investing hack!
(2/9)
ABBV at a Breakout Point: Golden Opportunity or Bull Trap?🔎 Short-Term Outlook (weeks to a few months)
Current Situation:
The stock is testing the strong resistance zone at $222–225, which has acted as a ceiling multiple times in the past.
Bullish Scenario:
A confirmed breakout and consolidation above $225 would validate bullish momentum.
🎯 Target 1: $235
ABBV AUG 2025ABBV is approaching a strong resistance zone after heavy selling volume near 210–215. The stock recently broke higher, but price is testing supply after a fast rally.
Institutional absorption was seen at 190 and 195, with 205 now acting as immediate support.
Upside target: 212–215 if buyers absorb
End of the Upward Impulse?
AbbVie is a large-cap healthcare company with ongoing sector-specific concerns.
Technically, impulsive upward waves seem to be completed.
Near-term indicators remain positive, but this optimism may only represent a point B.
Fair value for ABBV is around $190 and the current price reflects this.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4AB is 188.00 EUR — it has increased by 1.84% in the past 24 hours. Watch AbbVie, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange AbbVie, Inc. stocks are traded under the ticker 4AB.
4AB stock has risen by 1.51% compared to the previous week, the month change is a −3.89% fall, over the last year AbbVie, Inc. has showed a 11.63% increase.
We've gathered analysts' opinions on AbbVie, Inc. future price: according to them, 4AB price has a max estimate of 274.03 EUR and a min estimate of 169.59 EUR. Watch 4AB chart and read a more detailed AbbVie, Inc. stock forecast: see what analysts think of AbbVie, Inc. and suggest that you do with its stocks.
4AB stock is 2.39% volatile and has beta coefficient of 0.27. Track AbbVie, Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie, Inc. there?
Today AbbVie, Inc. has the market capitalization of 329.28 B, it has increased by 0.54% over the last week.
Yes, you can track AbbVie, Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie, Inc. is going to release the next earnings report on Feb 4, 2026. Keep track of upcoming events with our Earnings Calendar.
4AB earnings for the last quarter are 1.59 EUR per share, whereas the estimation was 1.50 EUR resulting in a 5.34% surprise. The estimated earnings for the next quarter are 2.26 EUR per share. See more details about AbbVie, Inc. earnings.
AbbVie, Inc. revenue for the last quarter amounts to 13.44 B EUR, despite the estimated figure of 13.28 B EUR. In the next quarter, revenue is expected to reach 13.97 B EUR.
4AB net income for the last quarter is 149.99 M EUR, while the quarter before that showed 787.78 M EUR of net income which accounts for −80.96% change. Track more AbbVie, Inc. financial stats to get the full picture.
Yes, 4AB dividends are paid quarterly. The last dividend per share was 1.49 EUR. As of today, Dividend Yield (TTM)% is 2.98%. Tracking AbbVie, Inc. dividends might help you take more informed decisions.
AbbVie, Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Feb 1, 2026, the company has 55 K employees. See our rating of the largest employees — is AbbVie, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie, Inc. EBITDA is 23.32 B EUR, and current EBITDA margin is 44.40%. See more stats in AbbVie, Inc. financial statements.
Like other stocks, 4AB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie, Inc. stock shows the buy signal. See more of AbbVie, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.









